Entering text into the input field will update the search result below

Akari up 15% on FDA nod on trial design for Coversin

Mar. 13, 2019 9:37 AM ETAkari Therapeutics, Plc (AKTX) StockBy: Douglas W. House, SA News Editor3 Comments
  • Thinly traded nano cap Akari Therapeutics (NASDAQ:AKTX +15.4%) is up out of the gate this morning following its announcement that the FDA has signed off on the endpoints for a pivotal study evaluating second-generation complement inhibitor Coversin for the treatment of pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), a disorder with a mortality rate of more than 80%.
  • The endpoint will be clinically meaningful treatment variables, including markers of complement activation and markers that are elevated in thrombotic microangiopathy like platelet count, red blood cell fragments, thrombocytopenia, elevated LDH (enzyme) and hypertension.
  • The study should launch in Q4.

Recommended For You

About AKTX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
AKTX--
Akari Therapeutics, Plc